dhr

#股票财报季
#DHR

Business assessment: Danaher has shown a recovery in its operations that is supported by tangible evidence, with particular positives including bioprocessing orders and improved free cash flow. However, reported revenue this quarter was boosted by the consolidation of an acquisition, while net profit benefited from a one-time tax gain. This is not yet enough to prove that the company has fully returned to rapid growth.

Investment assessment: The current valuation already reflects expectations of a sustained recovery and synergies from acquisitions. The available evidence is insufficient to conclude that Danaher is significantly undervalued. Its future investment value depends on whether core revenue growth can accelerate and whether its acquisition investments can generate sufficient long-term cash returns.

DHR’s recovery is finally getting clearer $DHR 🧪

Danaher opened 2026 with $6.0B in revenue, $2.06 in adjusted EPS, and $1.1B in free cash flow, which tells institutions the quality of earnings is still holding up. The real signal is the guidance bump and Biotechnology’s 7.0% core growth, while Diagnostics remains the drag; this is shaping up like a slow, selective rebound rather than a broad snapback.

Money tends to rotate toward the cleanest growth first, and biotech is clearly carrying the load while the other segments heal. If that strength spreads and the Masimo deal adds another layer of upside, the tape could keep attracting patient capital even without a loud market reaction.

Not financial advice. Manage your risk and protect your capital.

#DHR #Earnings #Stocks #Investing #Biotech

✦